Results From Multinational Phase 3 Trials: Benefit of Depleting Eosinophils in Severe Asthma Reinforced with New Biologic

PCSK9 Inhibitors Required to Reach LDL-C Goals in Many High-risk Patients

High Rates of Adherence: New Opportunities for Indefinite HIV Control

Efficacy and Safety of PCSK9 Inhibitors Now Measured In Years with No Change in Scale of Clinical Benefit

Landmark FLAME Data Support Guideline Change in COPD Patients with a History of Exacerbations

Biomarkers of Severe Asthma May Help Better Direct Emerging Therapies

In COPD, Renewed Emphasis on Symptom Control Provides Framework for Tailoring Therapy

Increasing NT-proBNP Isolated as Surrogate for Adverse Outcomes in Heart Failure

Expansion in Biologic Option Critical For Non-Responders to TNF Inhibitors

PCSK9 Inhibitors Show Similar Efficacy in Diabetics as in Other High-Risk Groups